About: Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aptamers Chemistry: Chemical Modifications and Conjugation Strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Creator	Alshaer, Walhan Esawi, Ezaldeen Nsairat, Hamdi Odeh, Fadwa Qaqish, Baraa Al Bawab, Abeer Ismail, Mohammad Ismail, Said
Source	Medline; PMC
abstract	Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but they are superior regarding a longer shelf life, simple production and chemical modification, in addition to low toxicity and immunogenicity. In the past three decades, aptamers have been used in a plethora of therapeutics and drug delivery systems that involve innovative delivery mechanisms and carrying various types of drug cargos. However, the successful translation of aptamer research from bench to bedside has been challenged by several limitations that slow down the realization of promising aptamer applications as therapeutics at the clinical level. The main limitations include the susceptibility to degradation by nucleases, fast renal clearance, low thermal stability, and the limited functional group diversity. The solution to overcome such limitations lies in the chemistry of aptamers. The current review will focus on the recent arts of aptamer chemistry that have been evolved to refine the pharmacological properties of aptamers. Moreover, this review will analyze the advantages and disadvantages of such chemical modifications and how they impact the pharmacological properties of aptamers. Finally, this review will summarize the conjugation strategies of aptamers to nanocarriers for developing targeted drug delivery systems.
has issue date	2019-12-18(xsd:dateTime)
bibo:doi	10.3390/molecules25010003
bibo:pmid	31861277
has license	cc-by
sha1sum (hex)	aefeb0e9f2d0db1868113232cdb87597e7614068
schema:url	https://doi.org/10.3390/molecules25010003
resource representing a document's title	Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
has PubMed Central identifier	PMC6982925
has PubMed identifier	31861277
schema:publication	Molecules
resource representing a document's body	covid:aefeb0e9f2d0db1868113232cdb87597e7614068#body_text
is schema:about of	named entity 'CHEMICAL' named entity 'USED' named entity 'ANTIBODIES' named entity 'DEVELOPING' named entity 'REALIZATION' named entity 'MAIN' named entity 'CLINICAL' named entity 'CAPABLE' named entity 'TRANSLATION' named entity 'STRATEGIES' named entity 'FUNCTIONAL GROUP' named entity 'ADDITION' named entity 'CLASS' named entity 'IN THE PAST' named entity 'REVIEW' named entity 'THERAPEUTIC' named entity 'LIGANDS' named entity 'SINGLE-STRANDED RNA' named entity 'BIOSENSORS' named entity '5B4' named entity 'APTAMER' named entity 'DIAGNOSTIC' named entity 'OLIGONUCLEOTIDES' named entity 'FOLDING' named entity 'VARIOUS' named entity 'MECHANISMS' named entity 'FOCUS' named entity 'MOLECULES' named entity 'DNA' named entity 'BUT' named entity 'ENTIRE' named entity 'ENABLING' named entity 'COVERS' named entity 'RENAL CLEARANCE' named entity 'CONJUGATION' named entity 'SHELF LIFE' named entity 'VARIETY' named entity 'SUCCESSFUL' named entity 'APTAMERS' named entity 'BIOLOGICAL' named entity 'SUPERIOR' named entity 'CHEMISTRY' named entity 'APTAMERS' named entity 'STRATEGIES' named entity 'IMPACT' named entity 'THERAPEUTICS' named entity 'EVOLVED' named entity 'LEVEL' named entity 'RECENT' named entity 'DELIVERY' named entity '5B10' named entity 'ARTS' named entity 'APPLICATIONS' named entity 'SMALL' named entity 'CHEMICAL' named entity 'IMMUNOGENICITY' named entity 'SOLUTION' named entity 'PROPERTIES' named entity 'IONS' named entity 'INCLUDING' named entity 'RESEARCH' named entity 'HIGH' named entity 'COMPLEX' named entity 'LIMITATIONS' named entity 'PRODUCTION' named entity 'MAKE' named entity 'TO BIND TO' named entity 'ANALYTICAL' named entity 'SHORT' named entity 'NEW' named entity 'ORGANISM' named entity 'HAVE' named entity 'TARGETS' named entity 'LARGE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software